Your browser doesn't support javascript.
SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients.
Gozalbo-Rovira, Roberto; Gimenez, Estela; Latorre, Víctor; Francés-Gómez, Clara; Albert, Eliseo; Buesa, Javier; Marina, Alberto; Blasco, María Luisa; Signes-Costa, Jaime; Rodríguez-Díaz, Jesús; Geller, Ron; Navarro, David.
  • Gozalbo-Rovira R; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
  • Gimenez E; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Latorre V; Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain.
  • Francés-Gómez C; Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain.
  • Albert E; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Buesa J; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Marina A; Department of Genomics and Proteomics, Instituto de Biomedicina de Valencia (IBV-CSIC) and CIBER de Enfermedades Raras (CIBERER-ISCIII), Valencia, Spain; Decoy-SARS-CoV-2 Study Group from the Institute of Biomedicine of Valencia (Group Members List in Acknowledgements Section), Spain.
  • Blasco ML; Medical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Signes-Costa J; Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Rodríguez-Díaz J; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain. Electronic address: jesus.rodriguez@uv.es.
  • Geller R; Institute for Integrative Systems Biology (I2SysBio), Universitatde Valencia-CSIC, 46980, Valencia, Spain. Electronic address: ron.geller@uv.es.
  • Navarro D; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. Electronic address: david.navarro@uv.es.
J Clin Virol ; 131: 104611, 2020 10.
Article in English | MEDLINE | ID: covidwho-738089
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity. PATIENTS AND

METHODS:

This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers were measured in a GFP reporterbased pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts.

RESULTS:

The overall correlation between levels of both antibody measurements was good (Rho = 0.82; P = 0 < 0.001). SARS-CoV-2 RBD IgG and NtAb50 levels in sera collected up to day 30 after the onset of symptoms were comparable between ICU and non-ICU patients (P=>0.1). Four ICU patients died; two of these achieved NtAb50 titers ≥1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0-<0.2) or weak (Rho=>0.2-<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum levels pro-inflammatory biomarkers.

CONCLUSIONS:

The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 severity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Hospitalization / Inflammation / Antibodies, Viral Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Clin Virol Journal subject: Virology Year: 2020 Document Type: Article Affiliation country: J.jcv.2020.104611

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Hospitalization / Inflammation / Antibodies, Viral Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Clin Virol Journal subject: Virology Year: 2020 Document Type: Article Affiliation country: J.jcv.2020.104611